Related Experiment Video
Updated: Dec 2, 2025
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.1K
US rheumatologists' beliefs and knowledge about biosimilars: a survey
Allan Gibofsky1, Dorothy McCabe2
1Division of Rheumatology, Hospital for Special Surgery and Weill Cornell Medicine, New York, NY, USA.
Rheumatology (Oxford, England)
|November 4, 2020
Summary
US rheumatologists understand and accept biosimilar products, especially for new RA patients. However, they are hesitant to switch patients already stable on reference biologics, indicating a need for further education on biosimilar use.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- The Food and Drug Administration (FDA) has approved multiple biosimilar products for TNF-α inhibitors and rituximab.
- Understanding rheumatologists' perceptions is crucial for biosimilar adoption in clinical practice.
Purpose of the Study:
- To evaluate US rheumatologists' perceptions of biosimilar products.
- To assess awareness and acceptance of biosimilars among rheumatologists prescribing TNF-α inhibitors.
Main Methods:
- An online survey with 19 questions was administered to 9050 US rheumatologists.
- Responses from 320 board-certified rheumatologists were collected and descriptively summarized.
Main Results:
- Most rheumatologists were aware of FDA-approved biosimilars but less so regarding interchangeability.
- 84% knew approved biosimilars are not automatically interchangeable.
- 73% would initiate biosimilar treatment for biologic-naïve RA patients, versus 35% for switching patients on reference products.
Conclusions:
- US rheumatologists demonstrate good understanding and acceptance of biosimilars, particularly for initiating treatment in biologic-naïve patients.
- Hesitancy exists regarding switching patients on stable reference products to biosimilars.
- Further education is needed to inform rheumatologists' treatment decisions regarding biosimilars.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
138
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
138
01:11Genome-wide Association Studies-GWAS
15.0K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.0K
01:16Bioequivalence: Overview
1.5K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.5K
01:13Bioequivalence studies: Biowaivers
97
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
97
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
75
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
75
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
283
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
283